argenx (NASDAQ:ARGX) Price Target Raised to $680.00 at Robert W. Baird

argenx (NASDAQ:ARGX) had its target price upped by Robert W. Baird from $650.00 to $680.00 in a report published on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

ARGX has been the subject of a number of other reports. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and boosted their target price for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Evercore ISI upped their price objective on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Piper Sandler raised their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Finally, Truist Financial reissued a “buy” rating and issued a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average target price of $662.83.

argenx Stock Performance

NASDAQ ARGX opened at $613.18 on Tuesday. The company has a market capitalization of $37.26 billion, a price-to-earnings ratio of -696.80 and a beta of 0.58. The stock has a 50-day moving average of $642.47 and a 200 day moving average of $592.89. argenx has a one year low of $349.86 and a one year high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts predict that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenx

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GeoWealth Management LLC grew its position in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares in the last quarter. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter worth approximately $37,000. Global Retirement Partners LLC boosted its stake in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares during the period. FIL Ltd purchased a new stake in argenx during the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenx during the fourth quarter valued at approximately $38,000. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.